ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly immunology — Worldwide revenue ($M) [legacy total] ($M)
Form 10-Q / 10-K Note 2
Latest, FY2017
605
Period ended Dec 31, 2017
Change on a year earlier
+435.0%
113 in FY2016
History
2 years
Since FY2016
Sources
1
Form 10-K (filed 2018-02-20)
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Immunology — Worldwide revenue ($M) [legacy total] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2017 | Dec 31, 2017 | 605 | +435.0% | Form 10-K (filed 2018-02-20) ↗ |
| FY2016 | Dec 31, 2016 | 113 | – | Form 10-K (filed 2018-02-20) ↗ |
Cite this data
StockData. (2026). Eli Lilly Immunology — Worldwide revenue ($M) [legacy total] ($M), annual FY2016–FY2017 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ta_immunology_ww_legacy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.